Skip to main content

Table 1 Patient characteristics

From: Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures

Variable

Controls (N = 910)

Clinical DLB (N = 360)

LBD with a high likelihood of DLB (N = 446)

Age (years)a

79 (41, 102)

73 (50, 100)

78 (48, 103)

Sex

Male

388 (42.6%)

270 (75.0%)

292 (65.5%)

Female

522 (57.4%)

90 (25.0%)

154 (34.5%)

Braak NFT stage

0

N/A

N/A

13 (2.9%)

I

N/A

N/A

23 (5.2%)

II

N/A

N/A

138 (30.9%)

III

N/A

N/A

143 (32.1%)

IV

N/A

N/A

129 (28.9%)

V

N/A

N/A

0 (0.0%)

VI

N/A

N/A

0 (0.0%)

Thal amyloid phase

0

N/A

N/A

40 (10.7%)

1

N/A

N/A

37 (9.9%)

2

N/A

N/A

23 (6.1%)

3

N/A

N/A

129 (34.4%)

4

N/A

N/A

56 (14.9%)

5

N/A

N/A

90 (24.0%)

LBD subtype

Transitional

N/A

N/A

89 (20.0%)

Diffuse

N/A

N/A

357 (80.0%)

Lewy body counts

Middle frontal gyrus

N/A

N/A

5 (0, 35)

Superior temporal gyrus

N/A

N/A

10 (0, 50)

Inferior parietal gyrus

N/A

N/A

4 (0, 30)

Cingulate gyrus

N/A

N/A

12 (2, 32)

Parahippocampal gyrus

N/A

N/A

16 (1, 45)

Putaminal TH-ir

Dorsolateral

N/A

N/A

2.93 (0.26, 21.61)

Ventromedial

N/A

N/A

8.99 (0.26, 27.42)

Substantia nigra neuronal loss score

Ventrolateral

 0.0 = none

N/A

N/A

0 (0.0%)

 0.5 = none/mild

N/A

N/A

2 (1.0%)

 1.0 = mild

N/A

N/A

10 (5.1%)

 1.5 = mild/moderate

N/A

N/A

7 (3.6%)

  2.0 = moderate

N/A

N/A

21 (10.8%)

 2.5 = moderate/severe

N/A

N/A

23 (11.8%)

 3.0 = severe

N/A

N/A

132 (67.7%)

Medial

   

 0.0 = none

N/A

N/A

2 (1.1%)

 0.5 = none/mild

N/A

N/A

1 (0.6%)

 1.0 = mild

N/A

N/A

25 (14.0%)

 1.5 = mild/moderate

N/A

N/A

16 (8.9%)

 2.0 = moderate

N/A

N/A

26 (14.5%)

 2.5 = moderate/severe

N/A

N/A

25 (14.0%)

 3.0 = severe

N/A

N/A

84 (46.9%)

  1. Sample median (minimum, maximum) is given for continuous variables
  2. For LBD cases with a high likelihood of DLB, information was unavailable for Thal amyloid phase (N = 71), middle frontal gyrus Lewy body count (N = 211), superior temporal gyrus Lewy body count (N = 213), inferior parietal gyrus Lewy body count (N = 211), cingulate gyrus Lewy body count (N = 213), parahippocampal gyrus Lewy body count (N = 232), dorsolateral putaminal TH-ir (N = 250), ventromedial putaminal TH-ir (N = 250), ventrolateral substantia nigra neuronal loss score (N = 251), and medial substantia nigra neuronal loss score (N = 267).
  3. aAge represents age at blood draw for controls, age at DLB onset for clinical DLB cases, and age at death for LBD with a high likelihood of DLB cases